Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefpodoxime proxetil + dicloxacillin
- Development stage
- Unknown
- Lead developer
- Intra Life
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bactiloc-DXL is an oral, extended-release combination antibiotic tablet containing cefpodoxime proxetil (a third-generation cephalosporin) and dicloxacillin (a penicillinase-resistant penicillin). Developed by Intra Life, this combination is designed to treat various bacterial infections, including acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Dicloxacillin also targets PBPs but is uniquely resistant to degradation by bacterial penicillinase (beta-lactamase), thereby extending the spectrum of activity against penicillinase-producing strains such as *Staphylococcus aureus*. The extended-release formulation of dicloxacillin ensures sustained therapeutic levels and reduces dosing frequency.
- Brand names
- Bactiloc-DXLBactiloc-DXL 200Bactiloc-DXL200Bactiloc-DXL-200
- Other names
- Cefpodoxime + dicloxacillinCefpodoxime proxetil + dicloxacillinCefpodoxime proxetil and dicloxacillin
02
Targets
β-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefpodoxime proxetil + dicloxacillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefpodoxime proxetil + dicloxacillin.